Validity Diagnostics to showcase urine test validity tools at SOFT-TIAFT 2026

Validity Diagnostics will exhibit at the SOFT-TIAFT 2026 Joint Meeting in Chicago from Sept. 19-24, 2026, pitching its validity reagents as a defense against synthetic and adulterated urine in workplace drug testing. The company says the technology helps employers, courts and labs protect sample integrity as urine subversion becomes more sophisticated.

Why it matters: - Workplace urine drug testing depends on sample integrity, and synthetic or adulterated urine can undermine compliance, safety and legal decisions. - Validity Diagnostics is positioning its reagents as a way for laboratories, employers and drug courts to identify subversion before drug results are trusted. - The need is growing as synthetic urine products continue to evolve.

What happened: - Validity Diagnostics will exhibit its products at the SOFT-TIAFT 2026 Joint Meeting in Chicago on Sept. 19-24, 2026. - The Branford, Florida-based company plans to highlight advanced validity testing for Fortune 500 companies, federal and state government employers, federal and state drug courts and probation offices, and drug testing laboratories. - Validity Diagnostics says its products are designed to help combat workplace urine drug test subversion.

The details: - The True Essentials Panel includes Oxidant History, True Urine LD and True Urine SD reagents. - The panel is designed to help laboratories detect synthetic and/or adulterated urine samples. - The company says the reagents provide dependable, science-backed tools for urine validity testing. - CEO Donna Suggs said workplace urine drug testing is only as dependable as the integrity of the urine sample. - Suggs said the company is seeing increased sophistication in urine sample subversion and that the products are built to detect threats before they compromise compliance or safety. - Independent research cited in the release includes a 2025 study by Franke et al. from Jena University Hospital in Germany and a 2025 RTI International study in Research Triangle Park, North Carolina. - Those studies found True Urine LD and True Urine SD outperformed conventional validity tests when identifying synthetic urine. - The release says traditional detection methods are no longer sufficient as synthetic urine products keep changing.

Between the lines: - The announcement is as much about market positioning as product launch, with Validity Diagnostics framing itself as a specialist in urine sample integrity rather than a general drug-testing supplier. - Citing outside research gives the company a scientific hook for a problem that affects employers, courts and labs that rely on urine screening decisions. - The emphasis on synthetic urine suggests the company sees a shift from simple adulteration toward more engineered attempts to evade testing.

What's next: - Validity Diagnostics will use the Chicago meeting to promote its products to laboratory and program decision-makers. - The company also directs readers to more information. - Validity Diagnostics says it partners with reference laboratories, hospital laboratories and program administrators nationwide to support urine testing integrity and reliability.

The bottom line: - Validity Diagnostics is betting that better validity testing will become essential as urine drug test evasion becomes more sophisticated.